Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial
An erratum to this article was published (JAMA Cardiol, 1 May 2026 ↗)
Primary result · Change in TPVResult — go to the resultEstimated difference +68.9 mm³ 95% CI 23.2–114.5Authors' conclusion
In this randomized clinical trial in men with localized PCa treated with radiation plus ADT, the GnRH agonist leuprolide was associated with greater coronary plaque progression within 12 months compared with the GnRH antagonist relugolix.
Study context
- Population
- Men with nonmetastatic prostate cancer without prior androgen deprivation therapy (ADT) receiving pelvic radiotherapy with ADT ≥6 months62 analysed
- Participants
- 65 men
- Comparison
- Gonadotropin-releasing hormone (GnRH) agonist leuprolide vs GnRH antagonist relugolix
- Leuproliden = 31
- Relugolixn = 31reference
- Primary endpoint
- Change in coronary total plaque volume (TPV) by coronary CT angiography
- Follow-up
- 12 months after ADT initiation
Methodological detailsopen-label, 4 centres of a single academic institution
- Open-label
- 4 centres of a single academic institution
Primary result
Change in TPV · 12 months
Estimated difference
+68.9 mm³
95% CI 23.2–114.5
P = 0.02
As reported in the abstract
Secondary outcomes
| Outcome | Estimated difference (mm³) (95% CI) | P value |
|---|---|---|
| Change in noncalcified plaque volume (NCPV) · 12 monthsAdjusted for baseline plaque volume, age, statin use | +64.5 (31.6–97.3) | P = 0.004 |
Change in calcified plaque volume (CPV) and low-attenuation plaque volume (LAPV) · 12 months
- No significant difference between leuprolide and relugolix
Original publication
Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. JAMA Cardiol. Published 1 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →